The Pseudokinase TRIB3 Negatively Regulates the HER2 Receptor Pathway and Is a Biomarker of Good Prognosis in Luminal Breast Cancer

por Alba Orea-Soufi, Sonia Castillo-Lluva, Nélida Salvador-Tormo, Paola Martín-Cabrera, Silvia Recuero, Estíbaliz Gabicagogeascoa, Manuel Moreno-Valladares, Marina Mendiburu-Eliçabe, Adrián Blanco-Gómez, José Miguel Ramos-Pittol, Elena García-Taboada, Alberto Ocaña, Francisco J. Cimas, Ander Matheu, Isabel Álvarez-López, Guillermo Velasco, Mar Lorente
Publicado 2021

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

por Angelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, Carmen Crespo, Cesar Mendiola, Rocío López-Vacas, Julia Berges-Soria, Isabel Álvarez López, Mireia Margeli, Juan L Bayo Calero, Xavier González Farre, Ana Santaballa, Eva M Ciruelos, Ruth Afonso, Juan Lao, Gustavo Catalán, José V Álvarez Gallego, José Miramón López, Francisco J Salvador Bofill, Manuel Ruiz Borrego, Enrique Espinosa, Juan A Fresno Vara, Pilar Zamora
Publicado 2014